Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.FREQ · Entity 6388 | Chief Scientific Officer | July 27, 2023 | July 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date July 27, 2023 · Filed July 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,650 |
Ending reported balance
After 2023-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-27 · Sale · Disposed 1,373 · Balance 184,994 F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.502 to $0.543. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Row 2 · 2023-07-28 · Sale · Disposed 1,344 · Balance 183,650 F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.461 to $0.471. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.502 to $0.543. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.461 to $0.471. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2023 Filed Jul 31, 2023 20:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,344 | $0.46 | $618.24 |
DisclosureSEC source: 0001127602-23-021561 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,650 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.461 to $0.471. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 27, 2023 Filed Jul 31, 2023 20:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,373 | $0.53 | $727.69 |
DisclosureSEC source: 0001127602-23-021561 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,994 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.502 to $0.543. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 20:16 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,329 | $0.51 | $677.79 |
DisclosureSEC source: 0000950170-23-035163 · ownership.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,367 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.511 to $0.515. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 20:16 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,390 | $0.50 | $695.00 |
DisclosureSEC source: 0000950170-23-035163 · ownership.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,696 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.491 to $0.513. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,438 | $0.54 | $776.52 |
DisclosureSEC source: 0000950170-23-034475 · ownership.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,086 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.53 to $0.561. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,333 | $0.61 | $813.13 |
DisclosureSEC source: 0000950170-23-034475 · ownership.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,524 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.611 to $0.619. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:07 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,361 | $0.64 | $871.04 |
DisclosureSEC source: 0001127602-23-021133 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,857 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.63 to $0.64. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 20:07 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,335 | $0.65 | $867.75 |
DisclosureSEC source: 0001127602-23-021133 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,218 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.62 to $0.65. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 20:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,484 | $0.56 | $831.04 |
DisclosureSEC source: 0001127602-23-020997 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,553 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.55 to $0.56. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,415 | $0.67 | $948.05 |
DisclosureSEC source: 0001127602-23-020997 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,037 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.60 to $0.71. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 20:23 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 906 | $0.59 | $534.54 |
DisclosureSEC source: 0001127602-23-020819 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,452 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.58 to $0.63. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 20:23 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,329 | $0.39 | $518.31 |
DisclosureSEC source: 0001127602-23-020819 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,358 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.38 to $0.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 20:42 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,335 | $0.39 | $520.65 |
DisclosureSEC source: 0001127602-23-020671 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,687 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.38 to $0.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:42 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,363 | $0.37 | $504.31 |
DisclosureSEC source: 0001127602-23-020671 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,022 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.37 to $0.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 21:35 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020573 · form4.xml · derivative · entry 6 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,816 Underlying: Common Stock · 4,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F6 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 21:35 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020573 · form4.xml · nonDerivative · entry 4 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 21:35 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,304 | $0.37 | $482.48 |
DisclosureSEC source: 0001127602-23-020573 · form4.xml · nonDerivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,023 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.37 to $0.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 10, 2023 Filed Jul 13, 2023 01:20 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,304 | $0.37 | $482.48 |
DisclosureSEC source: 0000950170-23-032734 · ownership.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,385 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.37 to $0.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 21:35 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020573 · form4.xml · derivative · entry 5 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,362 Underlying: Common Stock · 4,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F6 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 21:35 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020573 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 21:35 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,306 | $0.36 | $470.16 |
DisclosureSEC source: 0001127602-23-020573 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,781 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.34 to $0.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. F3 · balance_after: Includes 6,329 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| July 07, 2023 Filed Jul 13, 2023 01:20 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,306 | $0.36 | $470.16 |
DisclosureSEC source: 0000950170-23-032734 · ownership.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,689 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.34 to $0.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. F3 · balance_after: Includes 6,329 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020471 · form4.xml · derivative · entry 5 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,908 Underlying: Common Stock · 4,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F4 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,384 | $0.34 | $470.56 |
DisclosureSEC source: 0001127602-23-020471 · form4.xml · nonDerivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,758 F2 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.33 to $0.35. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020471 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 06, 2023 Filed Jul 13, 2023 01:15 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,384 | $0.34 | $470.56 |
DisclosureSEC source: 0000950170-23-032730 · ownership.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,666 F2 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.33 to $0.35. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020471 · form4.xml · derivative · entry 4 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,454 Underlying: Common Stock · 4,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F4 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020471 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 04, 2023 Filed Jul 13, 2023 01:15 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-032730 · ownership.xml · derivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The Restricted Stock Units fully vested on July 4, 2023 and do not have an expiration date. F4 · derivative.expiration_date: The Restricted Stock Units fully vested on July 4, 2023 and do not have an expiration date. Read SEC document |
| July 04, 2023 Filed Jul 13, 2023 01:15 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-032730 · ownership.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:35 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002454 · form4.xml · derivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. F2 · derivative.expiration_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 70,000 | Not disclosed Strike: $35.85 | Not disclosed |
DisclosureSEC source: 0001127602-22-021375 · form4.xml · derivative · entry 6 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2031-01-14 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 70,000 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021375 · form4.xml · derivative · entry 5 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-01-14 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 57,500 | Not disclosed Strike: $25.05 | Not disclosed |
DisclosureSEC source: 0001127602-22-021375 · form4.xml · derivative · entry 4 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,500 shares Expires 2030-02-11 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 57,500 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021375 · form4.xml · derivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2030-02-11 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 146,826 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-021375 · form4.xml · derivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,826 shares Expires 2029-10-01 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:04 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 146,826 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021375 · form4.xml · derivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,826 Underlying: Common Stock · 146,826 shares Expires 2029-10-01 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 20:51 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,415 | $1.53 | $6,754.95 |
DisclosureSEC source: 0001127602-22-019051 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,050 F3 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.49 to $1.56. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:51 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019051 · form4.xml · derivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:51 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019051 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 4638 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2022. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,069 | $3.53 | $3,773.57 |
DisclosureSEC source: 0001127602-22-006339 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,827 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.73. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 974 | $3.87 | $3,772.30 |
DisclosureSEC source: 0001127602-22-006339 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,896 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.80 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005752 · form4.xml · derivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F5 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 900 | $4.19 | $3,773.70 |
DisclosureSEC source: 0001127602-22-005752 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,870 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.00 to $4.48. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 851 | $4.43 | $3,769.08 |
DisclosureSEC source: 0001127602-22-005752 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,770 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.29 to $4.54. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 22:02 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 863 | $4.33 | $3,737.65 |
DisclosureSEC source: 0001127602-22-005331 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,621 F3 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.28 to $4.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:02 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005331 · form4.xml · derivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:02 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005331 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 2,702 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2021. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:14 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014280 · form4.xml · derivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 03, 2021 Filed Feb 3, 2021 22:58 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,000 | $47.19 | $94,380.00 |
DisclosureSEC source: 0001127602-21-003789 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.